FLT3 and acute myeloid leukemia: Guidelines from the European leukemia network (ELN) in 2017 indicated that molecular abnormalities in genes such as NPM1, FLT3-ITD, CEBPA, RUNX1, TP53, and ASXL1 combined with karyotype abnormalities can be used as an effective and comprehensive stratification system for the diagnosis and treatment of AML (4).